Cancer Research and Treatment

The Korean Cancer Association (대한암학회)
권호 표지

Clinical Value of Cyclooxygenase-2 Expression in Human Breast Carcinoma

Ahn, Jin-Hee;Kim, Sung-Bae;Ahn, Sei-Hyun;Gong, Gyung-Yub;Ahn, Myung-Ju;Kang, Yoon-Koo;Lee, Jung-Shin;Kim, Woo-Kun

  • Published : 20040000
⟨ Previous Next ⟩

Abstract

Purpose: To determine whether COX-2 expression is associated with clinicopathological parameters, including c-erb-B2 overexpression and angiogenesis, and the disease- free survival of patients with operable breast cancer. Materials and Methods: Paraffin-embedded tissue samples were selected from 205 patients surgically resected for breast cancer, between 1991 and 1997, and followedup for at least 4 years. Samples were immunohistochemically stained with antibodies to COX-2, c-erb-B2 and CD34. Results: COX-2 and c-erb-B2 expressions were detected in 118/205 (57.6%) and 58/205 (28.3%) patients, respectively. COX-2 expression was significantly higher in c-erb-B2 positive than c-erb-B2 negative tumors (75.9% vs. 49.7%, p-value 0.001). COX-2 expression was posi- -tively correlated with microvessel count (13.3$\pm$8.0 vs. 6.6$\pm$7.0, p-value 0.050), but not with other clinicopathological characteristics, including tumor size, involved axil lary lymph nodes and estrogen or progesterone receptor status. Although COX-2 expression itself was not a prognostic marker, breast cancer patients with tumors that co-expressed both COX-2 and c-erb-B2 had a poorer 5-year disease-free survival rate than those that did not (60.2% vs. 78.3%, p-value 0.0527). Conclusion: Our data suggest that COX-2 expression occurs frequently in c-erb-B2 positive breast cancer, and co-expression of COX-2 and c-erb-B2 may be a useful prognostic marker in patients with operable breast cancer.

Keywords

References

  1. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-1596 https://doi.org/10.1056/NEJM199112053252301
  2. Mohammed SI, Knapp DW, Bostwick DG, Foster RS, Khan KN, Masferrer JL, Woerner BM, Snyder PW, Koki AT. Expression of cyclooxygenase-2 (COX-2) in human invasive transitional cell carcinoma (TCC) of the urinary blad- der. Cancer Res 1999;59:5647-5650
  3. Chan G, Boyle JO, Yang EK, Zhang F, Sacks PG, Shah JP, Edelstein D, Soslow RA, Koki AT, Woerner BM, Masferrer JL, Dannenberg AJ. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 1999;59:991-994
  4. Parrett ML, Harris RE, Joarder FS, Ross MS, Clausen KP, Robertson FM. Cyclooxygenase-2 expression in human breast cancer. Int J Oncol 1997;10:503-507
  5. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T. Prostaglandins and breast cancer. Lancet 1977;2:624-626
  6. Liu XH, Rose DP. Differential expression and regulation of cyclooxygenase-1 and -2 in two human breast cancer cell line. Cancer Res 1996;15:5125-5127
  7. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer 2001;84:1188-1192 https://doi.org/10.1054/bjoc.2000.1709
  8. Harris RE, Alshafie GA, Abou-Issa HM, Seibert K. Chemoprevention of breast cancer in rats by celecoxib, a cyclooxygenase-2 inhibitor. Cancer Res 2000;60:2101-2103
  9. Kang HJ, Gong G, Jang SJ, Jung PJ, Park CK. Expression of cyclooxygenase-2 in human breast carcinoma: Relevance to tumor tumor angiogenesis and expression of estrogen receptor. Cancer Res Treat 2001;33:286-295 https://doi.org/10.4143/crt.2001.33.4.286
  10. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Met Rev 2000;19:19-27 https://doi.org/10.1023/A:1026575610124
  11. Sawaoka H, Tsuji S, Tsujii M, Gunawan ES, Sasaki Y, Kawano S, Hori M. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999;79:1469-1477
  12. Brueggemeier RW, Quinn AL, Parrett ML, Joarder FS, Harris RE, Robertson FM. Correlation of aromatase and cyclooxygenase gene expression in human breast cancer specimens. Cancer Letters 1999;140:27-35 https://doi.org/10.1016/S0304-3835(99)00050-6
  13. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998;4: 844-847 https://doi.org/10.1038/nm0798-844
  14. Ristimaki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, Joensuu H, Isola J. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002;62:632-635
  15. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-4 https://doi.org/10.1056/NEJM199101033240101
  16. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344: 783-792 https://doi.org/10.1056/NEJM200103153441101
  17. Hwang D, Scollard D, Byrne J, Levine E. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human breast cancer. J Natl Cancer Inst 1998;90:455-460 https://doi.org/10.1093/jnci/90.6.455
  18. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62:1676-1681
  19. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Guski H, Hauptmann S. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease-free survival and overall survival in patients with breast carcinoma. Cancer 2003;97:2978-2987 https://doi.org/10.1002/cncr.11437
  20. Subbaramaiah K, Norton L, Gerald W, Dannengerg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem 2002;77:18649-18657
  21. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene 1999;18:305-314 https://doi.org/10.1038/sj.onc.1202307
  22. Winde G, Lugering N, Glodny B, Schmid KW, Muller O, Senninger N, Osswald H. Decreased HER-2 tyrosine kinase expression in rectal mucosa of FAP patients following low-dose sulindac chemoprevention. Caner Lett 1998;134: 201-207 https://doi.org/10.1016/S0304-3835(98)00254-7
  23. Mann M, Sheng H, Shao J, Williams CS, Pisacane PI, Sliwkowski MX, DuBois RN. Targeting cyclooxygenase-2 and HER-2/neu pathways inhibits colorectal carcinoma growth. Gastroenterol 2001;120:1713-1719 https://doi.org/10.1053/gast.2001.24844
  24. Witters LM, Lipton A. Enhanced antiproliferative effect from the combination of a COX-2 inhibitor and an EGFR/ HER-2/neu tyrosine kinase inhibitor on the growth of human breast cancer cell lines. Proc Am Soc Clin Oncol 2003;22:921
  25. Davies GL, Salter J, Hills M, Lowe F, A' Hern R, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2) expression in human breast cancerscorrelations with known biological variables and rationale for the use of COX-2 inhibitors. Proc Am Soc Clin Oncol 2002;21:174